Sign in
Stories
Domain Therapeutics Strengthens Leadership Team
Share
4D Molecular Therapeutics Raises $300 Mi...
4P-Pharma Secures €15 Million Funding
AB Science's Medical Breakthrough Webcas...
ANJESO Drug Insight and Market Forecast
Aldeyra Therapeutics R&D Day 2024
Aligos Therapeutics Financial Disclosure
Overview
API
Domain Therapeutics strengthens its leadership team with the appointment of Sean A. MacDonald as Chief Business Officer. The company focuses on developing immuno-oncology drug candidates targeting GPCRs, with recent strategic appointments signaling accelerated North American expansion.
Ask a question
How does Domain Therapeutics' focus on GPCRs compare to other immuno-oncology targets in the industry?
How might Sean MacDonald's appointment impact Domain Therapeutics' immuno-oncology drug development efforts?
What potential implications could Domain Therapeutics' North American expansion have on the pharmaceutical industry?
Article Frequency
0.2
0.4
0.6
0.8
1.0
Nov 2023
Dec 2023
Jan 2024
Coverage